Primary axillary hyperhidrosis - Pipeline Insight, 2024

Primary axillary hyperhidrosis - Pipeline Insight, 2024

DelveInsight’s, “Primary axillary hyperhidrosis – Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Primary axillary hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Primary axillary hyperhidrosis Understanding

Primary axillary hyperhidrosis: Overview

Primary hyperhidrosis is a rare disease which refers to excessive sweating on the palms of the hands, sole of foot, in the groin area and/or beneath the breasts. Primary axillary hyperhidrosis is a type of hyperhidrosis which is characterized by the excessive sweating on armpits. The exact cause of excessive underarm sweating is still unknown but is associated to increased cholinergic sympathetic stimulation of sweat glands in the axilla. Primary axillary hyperhidrosis affects both males and females equally and the onset of disorder usually begins during childhood or puberty.

Symptoms

Symptom for primary axillary hyperhidrosis include excessive sweating in the axilla area. The symptoms begin during childhood or puberty and may persist throughout a person’s life.

Diagnosis

Diagnosing Primary axillary hyperhidrosis requires thorough evaluation of clinical history prior to confirm. In addition, some quantitative tests such as gravimetric measurement, evaporimetry, and infrared imaging technique may be effective in confirming the diagnosis of primary hyperhidrosis.

Treatment

Treatment for mild to moderate primary axillary hyperhidrosis antiperspirants, Iontophoresis, psychotropic drugs as well as anticholinergic drugs. Low-dosage of FDA approved botulinum toxin is also used to treat primary axillary hyperhidrosis. For intractable primary hyperhidrosis surgery may be the last resort of treatment which includes axillary sweat gland excision, sympathectomy, and endoscopic thoracic sympathectomy (ETS).

Primary axillary hyperhidrosis Emerging Drugs Chapters

This segment of the Primary axillary hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary axillary hyperhidrosis Emerging Drugs

• Sofpironium Bromide: Brickell Biotech Inc.

Brickell Biotech’s lead drug candidate, Sofpironium Bromide, is a topically administered small molecule in development for the treatment of primary axillary hyperhidrosis. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.

• DMT-410: Dermata Therapeutics LLC

Dermata’s drug DMT-410 is a combination regimen (DMT 310+ botulinum toxin) for the treatment of axillary hyperhidrosis. The new combination drug has shown positive results in its phase I trial.

Further product details are provided in the report……..

Primary axillary hyperhidrosis: Therapeutic Assessment

This segment of the report provides insights about the different Primary axillary hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Primary axillary hyperhidrosis

There are approx. 5+ key companies which are developing the therapies for Primary axillary hyperhidrosis. The companies which have their Primary axillary hyperhidrosis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Brickell Biotech Inc. and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Primary axillary hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary axillary hyperhidrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary axillary hyperhidrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary axillary hyperhidrosis drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Primary axillary hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Primary axillary hyperhidrosis.

Primary axillary hyperhidrosis Report Insights

• Primary axillary hyperhidrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Primary axillary hyperhidrosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Primary axillary hyperhidrosis drugs?
• How many Primary axillary hyperhidrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary axillary hyperhidrosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary axillary hyperhidrosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary axillary hyperhidrosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Brickell Biotech Inc.
• Dermata Therapeutics LLC
• Dr. August Wolff GmbH & Co. KG Arzneimittel

Key Products

• Sofpironium Bromide
• DMT-410
• wo3979, wo3970, wo3992 (Glycopyrronium Bromide)